Rose McNulty

The prognosis for cholangiocarcinoma remains poor despite advances in targeted therapy, but several targets hold promise for improving treatment strategies and patient outcomes.

A small study of children with eosinophilic esophagitis found that certain patients might benefit from gastric emptying nuclear medicine studies.

Although the autoimmune response that reduces β cell numbers has often been the focus of research in type 1 diabetes (T1D), findings from a new study suggest proinflammatory signaling in islet β cells may play a significant role in disease progression.

Hypomethylating agents are a widely used treatment option in acute myeloid leukemia secondary to myeloproliferative neoplasms (MPNs), but careful monitoring of thromboembolic risk is needed for optimal outcomes.

A recent study identified trends in blood counts, but did not find statistically significant associations between achieving hematological remission and clinical outcomes in polycythemia vera (PV) or essential thrombocythemia (ET).

Real-world patients often differ from those eligible for clinical trials, and comparing results in both populations is a key step in fine-tuning treatment strategies for multiple myeloma.

Multisystem inflammatory syndrome (MIS) in children is a rare condition known to be associated with COVID-19, but more research is needed to identify at-risk patients and guide public health interventions.

Whole-exome and RNA sequencing of early and late multiple myeloma tumor samples aimed to provide insight into disease drivers and phenotypes.

The Diabetes-Specific Risk-Taking Inventory proved useful in assessing risk-taking behavior in adolescents with type 1 diabetes (T1D), but future research on potential interventions is needed.

In patients with BRAF-mutated non–small-cell lung cancer (NSCLC), further research is needed to identify more treatment options that address the scope of subsets in this population.

Research presented at the 2022 American Society of Clinical Oncology Annual Meeting shows White patients with myelodysplastic syndrome (MDS) have worse overall survival outcomes than African American patients, contrary to previous findings in other cancer types.

Creating and validating effective risk assessment models could help facilitate appropriate prophylaxis for hemophilia, but more research is needed to confirm the prognostic value of various clinical risk factors and biomarkers.

A recent review explored current palliative care practices for patients with hematologic cancers compared with solid tumor cancers.

Early results of a multicenter phase 2 trial exploring the efficacy of daratumumab, pomalidomide, dexamethasone, and ixazomib treatment suggest the regimen is safe and effective in relapsed or refractory multiple myeloma (MM).

An interim analysis of the KEYNOTE-716 trial of adjuvant pembrolizumab supports its use in the adjuvant setting for patients with resected melanoma.

Recent research used incidence and mortality data from the GLOBOCAN 2020 database to gain insight into worldwide patterns of non-Hodgkin lymphoma in 2020.

A recent review summarized the current knowledge and treatment paradigm of multiple myeloma, including recent advances and challenges in nanomedicine. 

Transfusion dependence is common for patients with myelodysplastic syndromes (MDS), but real-world data show inconsistent patient experiences and varied transfusion practices between countries.

Major adverse cardiac events are rare but serious in patients treated with immune checkpoint inhibitors (ICIs), and increased awareness is crucial to identify and treat these conditions in a timely manner.

Immune checkpoint inhibitors have changed the way certain cancers are treated, but more can be done to optimize treatment and improve patient responses.

A recent meta-analysis aimed to clarify the relationship between parental age and solid tumor pediatric cancers, but more studies are necessary to overcome the limitations of available research.

While no agents are approved just yet, a variety of promising drugs targeting CLDN18.2 are undergoing early research and clinical trials for several cancer types. 

Findings of a study on children and adolescents with type 1 diabetes (T1D) in Italy suggest lockdown periods during COVID-19 did not increase disordered eating symptoms or adversely affect disease management.

Finding therapeutic targets for acute myeloid leukemia (AML) has proven challenging, but a set of immune-regulating molecules may hold promise as biomarkers and targets.

A novel prognostic model based on N 6-methyladenosine-associated long non-coding RNAs demonstrated accuracy in determining high- and low-risk disease, suggesting the associated risk value may have potential as a novel biomarker.

Preventing graft-versus-host disease (GVHD) after allogeneic stem cell transplant is a key aspect of patient management, but current cyclosporine concentration guidelines may not be sufficient, according to a recent study.

A retrospective study found low treatment adherence and no significant benefits to adjuvant chemotherapy or chemoradiotherapy following cholangiocarcinoma resection.

A recent study aimed to provide insight and guidance for managing graft-versus-host disease in patients after liver transplantation.

Whole-exome sequencing of a family with early-onset cancers found a novel variant in programmed cell death 1 ligand 2 that could potentially indicate germline predisposition to lymphoma.

A recent review points to a host of potentially disease-modifying agents currently in clinical trials.